The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > ACADEMIA
ACADEMIA
- Refusal to See Patients due to Kostaive Shots Might Violate “Duty of Care”: Lawyer
December 17, 2024
- Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
- Consortium on Pediatric Drug Development Up and Running from This Fiscal Year
November 25, 2024
- Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
- Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
- Japan Crafting Registry of All Hemophilia Patients, Company Use Eyed Too
November 5, 2024
- Pricing Partially to Blame for Diabetes Drug Shortage: Society Chair
November 5, 2024
- 50% of Quit-Smoking Clinics Closed or Suspended, Will Champix Re-Supply Bring Them Back Online?
October 30, 2024
- Local Anesthetic Supply Won’t Recover Soon Despite New Site Approval: Specialist
October 28, 2024
- Academic Societies Urge COVID-19 Vaccinations, Deny Kostaive “Shedding”
October 22, 2024
- Non-HCPs Have Higher Expectations of Alzheimer’s Drugs than Specialists: Poll
October 7, 2024
- Pharmacies, Hospitals Scrambling to Address New LLP Coverage Rule, Concerns Swirl Around Misuse
October 1, 2024
- KOL Calls for Public Support for Truvada’s PrEP Use against HIV
September 26, 2024
- Early Use of High-Dose Mecobalamin Extends Survival in ALS: IIT Data
September 20, 2024
- NCC, Eisai Confirm Tumor Shrinkage with E7820 Using J-PDX Models
September 17, 2024
- Japan Study Finds No Evidence of Increased Cancer Risk for Sitagliptin
September 3, 2024
- A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
August 28, 2024
- As Kisunla Approval Nears, Japanese Alzheimer’s KOL Hails Increase in Options
August 9, 2024
- Japan’s Antibiotic Use Up 22.3% in 2023 after COVID Restrictions Lifted
August 7, 2024
- NCC Out-Licenses UPenn-Partnered Cell Therapy to Spinout Company
July 12, 2024
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…